Redrawing Therapeutic Boundaries: Microbiota and Cancer
News Release, International Society of Microbiota, France – January 30, 2023
The unexpected roles of the microbiota in cancer challenge explanations of carcinogenesis that focus on tumor-intrinsic properties. Most tumors contain bacteria and viruses, and the host’s proximal and distal microbiota influence both cancer incidence and therapeutic responsiveness. Sholl et al. evaluated the current claims and challenges of the cancer-associated microbiota in terms of diagnosis, causality, and therapeutics.
Continuing the history of cancer–microbe research, these findings raise a key question: to what extent is the microbiota relevant for clinical oncology? They approached this by critically evaluating three issues: how the microbiota provides a predictive biomarker of cancer growth and therapeutic responsiveness, the microbiota’s causal role(s) in cancer development, and how therapeutic manipulations of the microbiota improve patient outcomes in cancer.
Clarifying the conceptual and empirical aspects of the cancer-associated microbiota can orient future research and guide its implementation in clinical oncology.
© 2021 Elsevier Inc. All rights reserved.
Tarrgeting Microbiota 2023 will cover the role of microbiota in different diseases and its potential implication in therapy. You can submit your abstracts related to this topic here.
Media contact:
International Society of Microbiota
[email protected]
Targeting Microbiota 2023 Congress
October 18-19, 2023
Website | Linked In | Facebook
